Note 13 - Restructuring Costs

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Restructuring and Related Activities Disclosure [Text Block]

13. Restructuring Costs

In

January 2019,

the Company implemented a strategic organizational realignment plan to reduce operating expenses and prepare the Company for expanded indications for its CMRF technology platform for improved sexual function and stress urinary incontinence in women. The restructuring included a reduction in headcount of approximately

40

full-time employees. The total restructuring costs were approximately

$742,000

and have been recorded in operating expenses in the condensed consolidated statements of operations. As of

June 30, 2019,

approximately

$24,000

remains unpaid and is included in accrued liabilities. This amount is expected to be paid in the quarter ended

September 30, 2019.

The restructuring contributed to a reduction in total operating expenses in the

first

quarter of

2019

as planned and is expected to result in additional operating cost savings throughout the remainder of this year.